Last reviewed · How we verify
IDP-118 Monad HP Lotion
At a glance
| Generic name | IDP-118 Monad HP Lotion |
|---|---|
| Also known as | HP |
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis (PHASE2)
- Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-118 Monad HP Lotion CI brief — competitive landscape report
- IDP-118 Monad HP Lotion updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI